Amedisys Home Health and Hospice Care (AMED) Expected to Post Earnings of $0.66 Per Share

Brokerages expect Amedisys Home Health and Hospice Care (NASDAQ:AMED) to report earnings of $0.66 per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Amedisys Home Health and Hospice Care’s earnings. The highest EPS estimate is $0.69 and the lowest is $0.64. Amedisys Home Health and Hospice Care posted earnings of $0.47 per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 40.4%. The firm is scheduled to report its next earnings results after the market closes on Monday, May 7th.

According to Zacks, analysts expect that Amedisys Home Health and Hospice Care will report full-year earnings of $3.00 per share for the current year, with EPS estimates ranging from $2.97 to $3.02. For the next fiscal year, analysts forecast that the company will post earnings of $3.32 per share, with EPS estimates ranging from $3.21 to $3.40. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Amedisys Home Health and Hospice Care.

Get Amedisys Home Health and Hospice Care alerts:

Amedisys Home Health and Hospice Care (NASDAQ:AMED) last announced its earnings results on Tuesday, February 27th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.58 by ($0.02). The business had revenue of $404.24 million for the quarter, compared to analyst estimates of $394.96 million. Amedisys Home Health and Hospice Care had a return on equity of 15.14% and a net margin of 1.98%. During the same period last year, the firm earned $0.44 EPS.

A number of research firms have commented on AMED. BidaskClub cut shares of Amedisys Home Health and Hospice Care from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Jefferies Group set a $70.00 price target on shares of Amedisys Home Health and Hospice Care and gave the stock a “buy” rating in a research note on Wednesday, February 28th. Oppenheimer boosted their price target on shares of Amedisys Home Health and Hospice Care from $68.00 to $63.00 and gave the stock an “outperform” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded shares of Amedisys Home Health and Hospice Care from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a research note on Tuesday, March 6th. Finally, TheStreet lowered shares of Amedisys Home Health and Hospice Care from a “b” rating to a “c+” rating in a research note on Wednesday, February 28th. Four analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Amedisys Home Health and Hospice Care presently has a consensus rating of “Buy” and an average price target of $64.90.

Large investors have recently modified their holdings of the business. SG Americas Securities LLC purchased a new stake in Amedisys Home Health and Hospice Care during the first quarter worth about $123,000. LS Investment Advisors LLC increased its stake in shares of Amedisys Home Health and Hospice Care by 233.1% during the fourth quarter. LS Investment Advisors LLC now owns 3,564 shares of the health services provider’s stock worth $188,000 after buying an additional 2,494 shares during the period. Fox Run Management L.L.C. purchased a new stake in shares of Amedisys Home Health and Hospice Care during the fourth quarter worth approximately $269,000. Paloma Partners Management Co purchased a new stake in shares of Amedisys Home Health and Hospice Care during the fourth quarter worth approximately $310,000. Finally, Stone Ridge Asset Management LLC purchased a new stake in shares of Amedisys Home Health and Hospice Care during the fourth quarter worth approximately $364,000. Institutional investors own 95.40% of the company’s stock.

NASDAQ AMED traded up $0.10 during trading hours on Friday, reaching $66.25. The company had a trading volume of 156,590 shares, compared to its average volume of 218,864. Amedisys Home Health and Hospice Care has a 1-year low of $45.60 and a 1-year high of $68.50. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.45 and a quick ratio of 1.45. The stock has a market capitalization of $2,252.93, a P/E ratio of 29.98, a PEG ratio of 1.26 and a beta of 0.66.

Amedisys Home Health and Hospice Care Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Get a free copy of the Zacks research report on Amedisys Home Health and Hospice Care (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys Home Health and Hospice Care (NASDAQ:AMED)